Skip to content

QuidelOrtho Corp

QDEL· NasdaqCore metricsCIK 1906324

In vitro & in vivo diagnostic substances19 peers

Last sale
Nov 12, 2026 · -10.87%
Market cap
$728.32M
68.61M shares
Filings
504
$618.90M
Q3 2026−1.9% FY25 yoy
-$53.80M
Q3 2026N/M FY25 yoy
-$7.50M
Q3 2026N/M FY25 yoy
-$204.50M
Q3 2026derivedN/M FY25 yoy
-$0.78
Q3 2026N/M FY25 yoy
$166.40M
Q3 2026+72.7% FY25 yoy
$728.32M
—
0.3×
0.4×
-16.08%
—

Twelve months to Sep 27, 2026 · derived

Price

$10.6251.52%$11.28past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$2.73BFY 2025
$3.27B0FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-28$2,730,200,000reported
FY 20242024-12-29$2,782,900,000reported
FY 20232023-12-31$2,997,800,000reported
FY 20222023-01-01$3,266,000,000reported
FY 20212022-01-02$1,698,600,000reported
FY 20202021-01-03$1,661,700,000reported

Capital returns

Dividends and buybacks · FY2020 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$0.00$0.00—68.08M sh+0.9%—
FY2024—$0.00$0.00—67.45M sh+0.9%—
FY2023—$7.20M$7.20M—66.85M sh+0.5%10.2%
FY2022—$74.30M$74.30M—66.51M sh+59.5%10.0%
FY2021—$103.50M$103.50M—41.70M sh—20.2%

Segments

Revenue by Segments, FY2020 to FY2025FY2020North America · FY2020 · $1.46BEMEA · FY2020 · $92.90MChina · FY2020 · $62.40MOther · FY2020 · $45.70MFY2021North America · FY2021 · $1.50BEMEA · FY2021 · $69.60MChina · FY2021 · $58.00MOther · FY2021 · $70.80MFY2022North America · FY2022 · $2.54BEMEA · FY2022 · $206.80MChina · FY2022 · $220.00MOther · FY2022 · $302.70MFY2023North America · FY2023 · $1.88BEMEA · FY2023 · $327.30MChina · FY2023 · $310.10MJPAC · FY2023 · $272.70MLatin America · FY2023 · $210.60MChina · FY2023 · $310.10MOther · FY2023 · $483.30MFY2024North America · FY2024 · $1.62BEMEA · FY2024 · $335.80MChina · FY2024 · $325.00MJPAC · FY2024 · $279.40MLatin America · FY2024 · $222.90MFY2025North America · FY2025 · $1.49BEMEA · FY2025 · $360.70MChina · FY2025 · $334.70MJPAC · FY2025 · $293.00MLatin America · FY2025 · $252.90M
LineFY2025ShareChange
North America$1.49B55%−8.1%
EMEA$360.70M13%+7.4%
China$334.70M12%+3.0%
JPAC$293.00M11%+4.9%
Latin America$252.90M9.3%+13.5%
China———
Other———
Total$2.73B

From the 10-K filed Feb 19, 2026QDEL

In vitro & in vivo diagnostic substances

QuidelOrtho Corp is the 2nd largest of the 20 covered companies the SEC files under this code, by revenue. SIC 2835

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

QuidelOrtho Corp · CIK 1906324 · Engraved from SEC EDGAR